English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/47022
Title: Characterization of dequalinium as a XIAP antagonist that targets the BIR2 domain
Authors: Orzáez, Mar; Gortat, Anna; Sancho, Mónica; Carbajo, Rodrigo J.; Pineda-Lucena, Antonio; Palacios-Rodríguez, Yadira; Pérez-Payá, Enrique
Keywords: Anti-tumour
Issue Date: 22-Feb-2011
Publisher: Springer
Citation: Apoptosis - Heidelberg 16(5): 460-7 (2011)
Abstract: Inhibitor of apoptosis proteins (IAPs) regulate the activity of caspases in apoptosis. The human X chromosome-encoded IAP (XIAP) is one of the more potent members of the IAP family and it has been described as a central regulator of apoptosis. Thus, molecules that inhibit XIAP could offer therapeutic opportunities to treat unwanted apoptosis inhibition. In the present study we have applied the selective optimization of side activities (SOSA) approach to the discovery of XIAP inhibitors. In this sense, we have identified dequalinium hydrochloride (Dq) as an inhibitor of the XIAP/caspase-3 interaction both in vitro and in cellular assays
Description: 8 páginas, 5 figuras, 1 tabla. PMID:21340509[PubMed]
Publisher version (URL): The original publication is available at www.springerlink.com; http://dx.doi.org/10.1007/s10495-011-0582-4
URI: http://hdl.handle.net/10261/47022
ISSN: 1360-8185
DOI: 10.1007/s10495-011-0582-4
E-ISSN: 1573-675X
Appears in Collections:(IBV) Artículos
Files in This Item:
File Description SizeFormat 
Orzaez last version author Apoptosis 2011.pdf376,52 kBAdobe PDFThumbnail
Show full item record

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.